Literature DB >> 16571623

Relative reinforcing effects of cocaine, remifentanil, and their combination in rhesus monkeys.

G Winger1, C M Galuska, S R Hursh, J H Woods.   

Abstract

Human polydrug abusers often take combinations of opioids and stimulants, but it is not clear why. Behavioral economics with demand curve analysis is uniquely able to separate two of the possibilities: that the drug combination increases the reinforcing potency of the component drugs or that the drug combination is a more effective reinforcer than either drug alone. Rhesus monkeys self-administered a range of doses of cocaine, remifentanil, and combinations of the drugs through indwelling intravenous catheters; the number of responses required for each drug infusion increased across drug-availability sessions. Combining small doses of cocaine and remifentanil that by themselves resulted in very low rates of responding yielded rates of responding that were higher than the maximum maintained by any dose of the constituent drugs. Nevertheless, demand curve analysis demonstrated that the drug combination was equally elastic as the component drugs, indicating that it was not more effective as a reinforcer than either cocaine or remifentanil alone. This suggests that enhanced self-administration of this particular drug combination is due primarily to the drug enhancement of the potency of the other drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16571623     DOI: 10.1124/jpet.105.100461

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  31 in total

1.  Self-administration of cocaine and remifentanil by monkeys: choice between single drugs and mixtures.

Authors:  Kevin B Freeman; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2010-12-30       Impact factor: 4.530

2.  Individual differences in discount rate are associated with demand for self-administered cocaine, but not sucrose.

Authors:  Mikhail N Koffarnus; James H Woods
Journal:  Addict Biol       Date:  2011-08-04       Impact factor: 4.280

3.  Behavioral economic analysis of the reinforcing effects of "bath salts" mixtures: studies with MDPV, methylone, and caffeine in male Sprague-Dawley rats.

Authors:  Brenda M Gannon; Melson P Mesmin; Agnieszka Sulima; Kenner C Rice; Gregory T Collins
Journal:  Psychopharmacology (Berl)       Date:  2018-09-29       Impact factor: 4.530

4.  Understanding Addiction Using Animal Models.

Authors:  Brittany N Kuhn; Peter W Kalivas; Ana-Clara Bobadilla
Journal:  Front Behav Neurosci       Date:  2019-11-29       Impact factor: 3.558

5.  Preference for an Opioid/Benzodiazepine Mixture over an Opioid Alone Using a Concurrent Choice Procedure in Rhesus Monkeys.

Authors:  Peter F Weed; Charles P France; Lisa R Gerak
Journal:  J Pharmacol Exp Ther       Date:  2017-04-24       Impact factor: 4.030

6.  Essential values of cocaine and non-drug alternatives predict the choice between them.

Authors:  David N Kearns; Jung S Kim; Brendan J Tunstall; Alan Silberberg
Journal:  Addict Biol       Date:  2016-09-14       Impact factor: 4.280

Review 7.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

8.  Self-administration of cocaine and remifentanil by monkeys under concurrent-access conditions.

Authors:  Sally L Huskinson; Kevin B Freeman; William L Woolverton
Journal:  Psychopharmacology (Berl)       Date:  2014-06-26       Impact factor: 4.530

Review 9.  How to study sex differences in addiction using animal models.

Authors:  Marilyn E Carroll; Wendy J Lynch
Journal:  Addict Biol       Date:  2016-06-26       Impact factor: 4.280

10.  Self-administration of drug mixtures by monkeys: combining drugs with comparable mechanisms of action.

Authors:  W L Woolverton; Zhixia Wang; Theresa Vasterling; F Ivy Carroll; Ronald Tallarida
Journal:  Psychopharmacology (Berl)       Date:  2007-11-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.